Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Background: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting. With new trials testing encorafenib-containing regimens for early-stage CC, we sought to characterize the clinical outcomes of early-stage BRAF V600E CC. Methods: We performed a systematic review and meta-analysis. Key inclusion criteria were a diagnosis of stage 2/3 BRAF V600E CC. Co-primary endpoints were overall survival (OS) and recurrence/disease-free survival (DFS). Meta-analysis was performed with a random-effects model incorporating sample size, hazard ratio (HR), and 95% confidence intervals (CIs). Results: A total of 206 studies underwent full-text review. Of these, six randomized controlled trials were included, comprising 6836 and 843 patients with wild-type (WT) and BRAF V600E, respectively. BRAF V600E was associated with inferior OS (HR 1.49, CI 1.21–1.75) and DFS (HR 1.17, CI 1.03–1.33). This finding remains in patients with microsatellite instability—low/stable or proficient mismatch repair (OS: HR 1.66, CI 1.36–2.02, DFS: HR 1.45, CI 1.22–1.72). Conclusions: BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“Analyses were performed using the metafor [32] and meta [33] packages in R statistical software version 3.4.0.”
InfluentialImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“Small-molecule inhibitors of BRAF (vemurafenib, dabrafenib, encorafenib) were developed and first studied in BRAF V600-mutant melanoma, demonstrating impressive overall response rates (ORRs) but short progression-free survival (PFS) due to rapid MAPK-pathway reactivation [6–8].”
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003) · ANZ Journal of Surgery · doi:10.1046/j.1445-2197.2003.02748.x · Cited by 7,603 · cited 1×
“MINORS (Methological index for non-randomized studies) [35] was not used because the majority of the studies included in this meta-analysis are randomized clinical trials.”
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827 · cited 1×
“Analyses were performed using the metafor [32] and meta [33] packages in R statistical software version 3.4.0.”
InfluentialPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“Indeed, 20–25% of metastatic CRC with BRAF V600E have concurrent microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) [50,51], which are known biomarkers predicting response to ICI [51].”
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989 · cited 1×
“Small-molecule inhibitors of BRAF (vemurafenib, dabrafenib, encorafenib) were developed and first studied in BRAF V600-mutant melanoma, demonstrating impressive overall response rates (ORRs) but short progression-free survival (PFS) due to rapid MAPK-pathway reactivation [6–8].”
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · cited 1×
“Combinations of BRAF inhibitors with MEK inhibitors (co-bimetinib, trametinib, binimetinib) successfully prolonged PFS and ultimately overall survival (OS) compared to BRAF-inhibitor monotherapy [9,10].”
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068 · cited 1×
“Combinations of BRAF inhibitors with MEK inhibitors (co-bimetinib, trametinib, binimetinib) successfully prolonged PFS and ultimately overall survival (OS) compared to BRAF-inhibitor monotherapy [9,10].”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 1×
“This stark contrast between CRC and other BRAF-mutated cancer types has been shown to be related to EGFR-mediated reactivation of the MAPK pathway upon inhibition of BRAF [13,14].”
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“In metastatic CRC with BRAF V600E mutations, early studies demonstrated that single-agent BRAF inhibition had unimpressive clinical activity, with ORRs of 0–5% [11,12].”
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 2×
“MAPK-targeted approaches did not become an important part of the treatment armamentarium for metastatic colorectal cancer with BRAF V600E until the presentation of data from the BEACON trial [17].”
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.022 · Cited by 1,375 · cited 2×
“For the high-risk stage 2 or stage 3 patients included in the A022004/NCT05710406 study with MSS/pMMR, standard of care in the adjuvant setting includes 3–6 months of CAPOX or 6 months of FOLFOX chemotherapy [49].”
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158 · cited 3×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · cited 1×
“This stark contrast between CRC and other BRAF-mutated cancer types has been shown to be related to EGFR-mediated reactivation of the MAPK pathway upon inhibition of BRAF [13,14].”
Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · cited 1×
“Indeed, 20–25% of metastatic CRC with BRAF V600E have concurrent microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) [50,51], which are known biomarkers predicting response to ICI [51].”
Product review: Covidence (systematic review software)
Babineau, J. (2014) · Journal of the Canadian Health Libraries Association / Journal de l'Association des bibliothèques de la santé du Canada · doi:10.5596/c14-016 · Cited by 721 · cited 1×
“Abstracts were screened by two independent reviewers using Covidence [31].”
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“In metastatic CRC with BRAF V600E mutations, early studies demonstrated that single-agent BRAF inhibition had unimpressive clinical activity, with ORRs of 0–5% [11,12].”
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683 · cited 4×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
InfluentialHutchins, G., Southward, K., Handley, K., Magill, L., Beaumont, C., Stahlschmidt, J., Richman, S., Chambers, P., Seymour, M., Kerr, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1366 · Cited by 681 · cited 2×
“…a subset of patients with rectal cancers which follow a different treatment algo-rithm altogether in the early-stage setting [45], and included patients with non-V600 BRAF mutations, which are known to be associated with differential prognosis and response to MAPK-targeted therapy [5,44,46].”
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569 · cited 1×
“While the triplet therapy elicited an ORR of 27% and OS of 9.3 months, both statistically superior to the control group, only ORR was numerically superior in the triplet compared to the doublet groups (ORR 19.5%), and OS was identical (9.3 months) [18].”
InfluentialRichman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550 · cited 2×
“BRAF is a constituent of the MAP Kinase (MAPK) signaling pathway and is among the most commonly mutated genes in human cancers [1].”
Self-citationKopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389 · cited 1×
“Subsequent studies using EGFR and BRAF inhibition with vemurafenib and cetuximab in Class 1 BRAF-mutant CRC revealed mild improvements in ORR, but still did achieve the clinical efficacy of single-agent BRAF inhibition in other BRAF-mutated cancer types [15,16].”
Jones, J. C., Renfro, L. A., Al-Shamsi, H. O., Schrock, A. B., Rankin, A., Zhang, B. Y., Kasi, P. M., Voss, J. S., Leal, A. D., Sun, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4394 · Cited by 339 · cited 3×
“…a subset of patients with rectal cancers which follow a different treatment algo-rithm altogether in the early-stage setting [45], and included patients with non-V600 BRAF mutations, which are known to be associated with differential prognosis and response to MAPK-targeted therapy [5,44,46].”
Gavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320 · cited 2×
“Formica et al. meta-analyzed patients with BRAF-mutant stage 2 and 3 CC but included publications that used divergent statistical outcome measures [43,44], contained a subset of patients with rectal cancers which follow a different treatment algo-rithm altogether in the early-stage setting [45],…”
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279 · cited 1×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276 · cited 1×
“Subsequent studies using EGFR and BRAF inhibition with vemurafenib and cetuximab in Class 1 BRAF-mutant CRC revealed mild improvements in ORR, but still did achieve the clinical efficacy of single-agent BRAF inhibition in other BRAF-mutated cancer types [15,16].”
Ogino, S., Shima, K., Meyerhardt, J. A., McCleary, N. J., Ng, K., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2246 · Cited by 267 · cited 2×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., & Thibodeau, S. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1489 · Cited by 251 · cited 3×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Clarke, C. N., & Kopetz, S. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 207 · cited 1×
“While it has been clearly established that BRAF V600E is a poor prognostic indicator in metastatic CRC [24–26], mixed data exists for early-stage disease.”
Yaeger, R., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N., Weiser, M. R., Capanu, M., et al. (2014) · Cancer · doi:10.1002/cncr.28729 · Cited by 203 · cited 1×
“While it has been clearly established that BRAF V600E is a poor prognostic indicator in metastatic CRC [24–26], mixed data exists for early-stage disease.”
Taieb, J., Zaanan, A., Le Malicot, K., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 154 · cited 5×
“In terms of disease-free survival (DFS), the PETACC-8 and PETACC-3 studies showed no difference between BRAF-mutant and wild-type (WT) patients [27,28].”
InfluentialEncorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz, S., Yoshino, T., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03443-3 · Cited by 124 · cited 3×
“OS was also significantly prolonged compared to SOC [20], which has led to accelerated approval by the FDA for encorafenib and cetuximab with mFOLFOX6 in the first-line setting for metastatic CRC with BRAF V600E.”
InfluentialKRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis
Formica, V., Sera, F., Cremolini, C., Riondino, S., Morelli, C., Arkenau, H.-T., & Roselli, M. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab190 · Cited by 120 · cited 1×
“…a subset of patients with rectal cancers which follow a different treatment algo-rithm altogether in the early-stage setting [45], and included patients with non-V600 BRAF mutations, which are known to be associated with differential prognosis and response to MAPK-targeted therapy [5,44,46].”
Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01693 · Cited by 103 · cited 1×
“…Subsequently, the phase 2 ANCHOR CRC study demonstrated an ORR of 47% in metastatic CRC with BRAF V600E treated in the first line with the encorafenib, binimetinib, and cetuximab triplet, suggesting that moving MAPK-targeted therapies to the first line may yield benefits for these patients [19].”
Sinicrope, F. A., Mahoney, M. R., Yoon, H. H., Smyrk, T. C., Thibodeau, S. N., Goldberg, R. M., Nelson, G. D., Sargent, D. J., & Alberts, S. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0527 · Cited by 84 · cited 3×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Domingo, E., Camps, C., Kaisaki, P. J., Parsons, M. J., Mouradov, D., Pentony, M. M., Makino, S., Palmieri, M., Ward, R. L., Hawkins, N. J., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30117-1 · Cited by 76 · cited 1×
“…[43,44], contained a subset of patients with rectal cancers which follow a different treatment algo-rithm altogether in the early-stage setting [45], and included patients with non-V600 BRAF mutations, which are known to be associated with differential prognosis and response to MAPK-targeted…”
Dankner, M., Wang, Y., Fazelzad, R., Johnson, B., Nebhan, C. A., Dagogo‐Jack, I., Myall, N. J., Richtig, G., Bracht, J. W. P., Gerlinger, M., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00107 · Cited by 53 · cited 1×
“Patients with CRC whose tumors harbor Class 2 and 3 BRAF mutations have been shown to have prolonged survival compared to those with Class 1 BRAF mutations, but are generally believed to be less responsive to MAPK-targeted therapies compared to Class 1 BRAF-mutant CRC [4,5].”
Self-citationElez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., et al. (2024) · Future Oncology · doi:10.2217/fon-2022-1249 · Cited by 46 · cited 1×
“The ongoing SEAMARK trial aims to study the combination of encorafenib, cetuximab, and pembrolizumab in the first line for metastatic CRC with MSI-H/dMMR and BRAF V600E [52].”
Zhu, L., Dong, C., Cao, Y., Fang, X., Zhong, C., Li, D., & Yuan, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154795 · Cited by 34 · cited 1×
“Another meta-analysis by Zhu et al. similarly included publications that exclusively presented multivariate hazard ratios [43], patients with rectal cancers [47,48], and was published in 2016, resulting in an incomplete review of all currently available literature.”
Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Darlix, A., Ratoša, I., Ferraro, E., Griguolo, G., Guarneri, V., Pellerino, A., Höfer, S., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.04.008 · Cited by 30 · cited 1×
“Quality assessment of all included studies was performed using a modified Newcastle–Ottawa scale as previously described [34].”
Self-citationPentheroudakis, G. E., Raptou, G., Kotoula, V., Wirtz, R. M., Vrettou, E., Karavasilis, V., Gourgioti, G., Gakou, C., Syrigos, K. N., Bournakis, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124612 · Cited by 26 · cited 1×
“Another meta-analysis by Zhu et al. similarly included publications that exclusively presented multivariate hazard ratios [43], patients with rectal cancers [47,48], and was published in 2016, resulting in an incomplete review of all currently available literature.”
Dankner, M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00195 · Cited by 24 · cited 2×
“BRAF mutations are found in 10% of colorectal cancers (CRCs) and can be grouped into three classes based on their molecular characteristics [2,3].”
Self-citationThe Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers
Kazandjian, S., Rousselle, E., Dankner, M., Cescon, D. W., Spreafico, A., Ma, K., Kavan, P., Batist, G., & Rose, A. A. N. (2024) · Cancers · doi:10.3390/cancers16020445 · Cited by 15 · cited 1×
“BRAF mutations are found in 10% of colorectal cancers (CRCs) and can be grouped into three classes based on their molecular characteristics [2,3].”
Self-citationSfakianaki, M., Papadaki, C., Tzardi, M. N., Trypaki, M., Alam, S., Lagoudaki, E. D., Messaritakis, I., Zoras, O., Mavroudis, D., Georgoulias, V., et al. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.008 · Cited by 13 · cited 2×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Hu, H., Wu, Z., Wang, C., Huang, Y. J., Zhang, J., Cai, Y., Xie, X., Li, J., Shen, C., Li, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579478 · Cited by 9 · cited 2×
“No additional patients were included from retrospective studies in the pMMR/MSS patient population, but an additional study of dMMR/MSI-H patients strengthened the null hypothesis of no-DFS-effect observed in these patients (HR 1.04, 95% CI 0.60–1.82) [ 42].”
InfluentialCiappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., Mauro, A. D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052216 · Cited by 9 · cited 1×
“Ongoing research in liquid biopsy is poised to allow for non-invasive monitoring of disease progression and improved understanding of resistance mechanisms in the context of MAPK-targeted therapies [23].”
Yaeger, R. D., Shi, Q., Dueck, A. C., Dib, E. G., Kazmi, S. M. A., Alese, O. B., Krishnamurthi, S., Nixon, A. B., Shergill, A. P., O'Reilly, E. M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.tps3641 · Cited by 6 · cited 2×
“The ongoing, highly anticipated A022004 randomized trial is enrolling patients with stage 2/3 BRAF V600E-mutant CC to evaluate treatment with encorafenib and cetuximab [22].”
Boku, S., Satake, H., Ohta, T., Mitani, S., Kawakami, K., Suzuki, Y., Matsumoto, T., Terazawa, T., Yamazaki, E., Hasegawa, H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0949 · Cited by 4
Prognostic Factors for Survival in Transverse Colon Cancers
Küçükarda, A., Gökyer, A., Sayın, S., Gökmen, İ., Özcan, E., Köstek, O., Hacıoğlu, M. B., Uzunoğlu, S., Çiçin, İ., & Erdoğan, B. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00675-1 · Cited by 3 · cited 1×
“Citations: PETACC-8 [27], NCCTG N0147 [36,37], PETACC-3 [28], CALGB89803 [38], Intergroup 0135/NCCTG 91-46-53/NCIC CTG CO.9 [39], MO-SAIC [29], University of Crete [40], Trakya University School of Medicine [41], Guangzhou Medical University [42].”
Cited by
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 6
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
Tao, D., He, H., Chen, J., & Li, X. G. (2026) · BMC Cancer · doi:10.1186/s12885-026-16563-5
“This approach operates on the premise that simultaneous elevation of multiple markers may indicate more extensive disease or greater biological aggressiveness, potentially corresponding to worse clinical outcomes [13].”
Dirven, I., Ang, C., Bertels, C., Kortbeek, K., de Haar-Holleman, A., Vollebergh, M. A., Poulikakos, P. I., & Neyns, B. (2026) · Cancer · doi:10.1002/cncr.70569
Metadata
- Authors
- Dankner, M., Dubé, L.-R., Sorin, M., Stein, A. J. B., Nowakowski, A., Park, C. L., Magrill, J., Lazaratos, A.-M., Romero, J. M., Batist, G., Kavan, P., Rose, A. A. N., & Ma, K.
- Affiliations
- Jewish General Hospital (CA)
- McGill University (CA)
- Institut du cancer Rosalind & Morris Goodman (CA)
- Corresponding author
- Ma, Kim
- ORCID
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2025-11-06
- Volume
- 32
- Issue
- 11
- Pages
- 624
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- OpenAlex
- W4415991529
- Cited by
- 3
- References
- 50
- Citations by year
- 2026: 3
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- BRAF V600E mutation, early colon cancer, prognostic value, overall survival, disease-free survival, microsatellite instability, DNA mismatch repair, encorafenib, cetuximab, stage II and III colon cancer
- MeSH terms
- Colonic Neoplasms, Humans, Mutation, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.